financetom
Business
financetom
/
Business
/
Will be able to see order inflow of Rs 9,000 crore: Kalpataru Power
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Will be able to see order inflow of Rs 9,000 crore: Kalpataru Power
Mar 4, 2021 6:18 AM

Kalpataru Power has bagged new projects worth around Rs 1,550 crore. The order win is from India and Latin America in the power transmission business.

Share Market Live

NSE

Manish Mohnot, MD & CEO of Kalpataru Power said, "Today we have L1 around Rs 1,500 crore so my own assessment is reaching Rs 9,000 crore should not be a challenge. We already did Rs 8,000 crore and getting further Rs 1,000 crore in the next 3-4 weeks will not be a challenge. So, we should be at Rs 9,000 crore for sure.”

Mohnot said, “All these orders have come in the transmission line sector, out of the Rs 1,500 crore around Rs 1,100 crore is from the transmission domestic, orders around Rs 400 crore is from overseas. Average margins in all our orders continue to be in the range of 9-11 percent, it is different for different projects. We expect that majority of these orders should get converted to revenues in the next year."

On monetisation of assets and sale on Shubham Logistics, Mohnot said, "On the monetisation front on our Indore project, out of five towers we have got OC for four towers. We expect to monetise the entire asset in 21-22. We have closer to Rs 300 crore plus which are blocked on this assets as of now.”

"As far as Shubham Logistics is concerned, we have already appointed advisor, we have got active interest by 4-5 prospective buyers. We expect by end of Q1 or Q2 to have complete clarity on that in terms of whether we get strategic investors or we look at exiting full."

For full management commentary, watch the video.

(Edited by : Priyanka Rathi)

First Published:Mar 4, 2021 3:18 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enphase Energy to lay off 17% of workforce
Enphase Energy to lay off 17% of workforce
Nov 9, 2024
(Reuters) -Enphase Energy will cut its global workforce by about 17%, impacting about 500 employees and contractors, the solar inverter maker disclosed in a filing on Friday. Enphase will also streamline its operations by focusing contract manufacturing in four existing locations - two in the United States, one in India and one in China. The company will cease its contract...
Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing
Beam Therapeutics Insider Sold Shares Worth $1,347,050, According to a Recent SEC Filing
Nov 9, 2024
04:23 PM EST, 11/08/2024 (MT Newswires) -- Giuseppe Ciaramella, President, on November 06, 2024, sold 51,110 shares in Beam Therapeutics ( BEAM ) for $1,347,050. Following the Form 4 filing with the SEC, Ciaramella has control over a total of 109,150 shares of the company, with 109,150 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1745999/000095017024124085/xslF345X05/ownership.xml ...
Moog Insider Sold Shares Worth $298,979, According to a Recent SEC Filing
Moog Insider Sold Shares Worth $298,979, According to a Recent SEC Filing
Nov 9, 2024
04:01 PM EST, 11/08/2024 (MT Newswires) -- Brian J Lipke, Director, on November 07, 2024, sold 1,343 shares in Moog ( MOG/A ) (MOGA, MOGB) for $298,979. Following the Form 4 filing with the SEC, Lipke has control over a total of 19,765 shares of the company, with 19,765 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/67887/000006788724000085/xslF345X05/wk-form4_1731099060.xml ...
Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate
Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate
Nov 9, 2024
04:53 PM EST, 11/08/2024 (MT Newswires) -- Fate Therapeutics ( FATE ) said late Friday that preclinical data for its CAR T-cell candidate FT836 demonstrated the product's potential for durable anti-tumor activity without intervention. The data support the pan-cancer activity of MICA/B targeting, and indicate that our next-generation, iPSC-derived CAR T-cell platform has the potential to drive potent and durable...
Copyright 2023-2026 - www.financetom.com All Rights Reserved